Braidwell LP Nuvalent, Inc. Transaction History
Braidwell LP
- $1.63 Billion
- Q1 2025
A detailed history of Braidwell LP transactions in Nuvalent, Inc. stock. As of the latest transaction made, Braidwell LP holds 840,945 shares of NUVL stock, worth $64.9 Million. This represents 3.66% of its overall portfolio holdings.
Number of Shares
840,945
Previous 241,235
248.6%
Holding current value
$64.9 Million
Previous $18.9 Million
215.83%
% of portfolio
3.66%
Previous 1.06%
Shares
2 transactions
Others Institutions Holding NUVL
# of Institutions
216Shares Held
60.9MCall Options Held
319KPut Options Held
211K-
Deerfield Management Company, L.P. (Series C) New York, NY18MShares$1.39 Billion32.3% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY5.27MShares$407 Million19.15% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.44MShares$343 Million0.01% of portfolio
-
Black Rock Inc. New York, NY3.02MShares$233 Million0.01% of portfolio
-
Commodore Capital LP New York, NY1.86MShares$143 Million12.88% of portfolio
About Nuvalent, Inc.
- Ticker NUVL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 42,977,800
- Market Cap $3.32B
- Description
- Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferr...